Virus-specific lymphocytes in the treatment of post-transplant infections.
Determination of cellular immunity after undergoing COVID-19.
Research focus The CTEF-cGMP facility represents a unit for Cell-based Medicinal Products (CBMPs) or Advanced Therapy Products (ATPs) including cell therapy and tissue engineered products. These products are manufactured from viable autologous, allogeneic or xenogeneic cells and they can also contain non-cellular components (chemical/biological compounds, matrices, scaffold etc.). All manufacturing and production control activities in CTEF are carried out in accordance with the principles of cGMP quality. This is in order to provide the authorization for the manufacturing of investigation of all medical products within the clinical trials. Environmental Monitoring and Assessment is conducted continuously during the production processes.
• Development of clinical-scale manufacturing processes based on cell and tissue engineering.
• Development of analytical methods for product characterization and release.
• GMP manufacturing and quality control of releasing clinical–grade products.
• Institute of Hematology and Blood Transfusion, Praha, Czech Republic
• Masarykova Univerzita, Brno, Czech Republic
• The Institute of Genetic Medicine, Newcastle, United Kingdom
Offered services and expertise
• The facility provides licensed manufacturing and testing of cGMP grade cell-based medical products for pre-clinical and clinical trials and is available to scientists in the academic and private sector.
• Taking care of project licenses and authorization processes.
FARKAS S, SIMARA P, REHAKOVA D, VEVERKOVA L, KOUTNA I. Endothelial Progenitor Cells Produced From Human Pluripotent Stem Cells by a Synergistic Combination of Cytokines, Small Compounds, and Serum-Free Medium. Front Cell Dev Biol. 2020 May
TESAROVA L, JARESOVA K, SIMARA P, KOUTNA I. Umbilical Cord-Derived Mesenchymal Stem Cells Are Able to Use bFGF Treatment and Represent a Superb Tool for Immunosuppressive Clinical Applications. Int J Mol Sci. 2020 Jul 28;21(15):5366REHAKOVA D, SOURALOVA T, KOUTNA I. Clinical-Grade Human Pluripotent Stem Cells for Cell Therapy: Characterization Strategy. Int J Mol Sci. 2020 Mar 31;21(7):243
TESAROVA, L., SIMARA, P., STEJSKAL, S., KOUTNA, I.The Aberrant DNA Methylation Profile of Human Induced Pluripotent Stem Cells Is Connected to the Reprogramming Process and Is Normalized During In Vitro Culture.PLoS One. 2016, 11(6), e0157974.
INTERNATIONAL CLINICAL RESEARCH CENTER
OF ST. ANNE’S UNIVERSITY HOSPITAL BRNO